In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.
The prevalence of depression and anxiety were also higher among younger patients and those who had a longer duration of pain.
Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.
The event will focus on clinical practice expansion for community pharmacies and how to make them a revenue-generating health care destination.
Coalition for Epidemic Preparedness Innovations experts warned of the potential for bird flu to become a pandemic event if officials don’t prepare quickly.
The ADjoin long-term extensive study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.
Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.
Investigators report that the safety profile is also similar between both drugs.
After adjusting for confounding factors, women who experienced premature menopause had an increased risk of T2D.
The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.
Clinical pharmacists were asked to provide interventions to improve their patients’ rate of not showing up to a pharmacy appointment.
Cebranopadol met its primary endpoint of reduction in pain intensity as measured by the Pain Numeric Rating Scale (NRS) area under the curve from 2 through 48 hours.
Researchers conducted a survey asking pharmacists their perspectives on addressing patients’ social determinants of health.
Currently, there is a gap in treatment for this patient population and intracerebral hemorrhagic stroke is considered an orphan disease.
The approval is the first significant innovation for the delivery of epinephrine for this population in more than 35 years, according to the company news release.
Researchers investigated the acceptability of community pharmacy-led influenza vaccination and patients’ willingness to return for future immunization.
The main motivations for preferring vaccination included previous experience with an RSV infection and desire to protect the baby.
Researchers analyzed the association between adherence to a Mediterranean diet and obesity cancers, with a focus on the mediating role adiposity plays throughout the process.
All dosages of semaglutide (Wegovy) under the new program will be available at $499 per month for patients that are uninsured or who do not have coverage for obesity medication.
Investigators found that zonisamide was associated with a reduction in monthly migraine days for pediatric populations.
In a third installment of our interview series with Chris Robinson, MD, PhD, we looked at the future of pain management and emerging technologies being used for treatment.
“The Commission reinforces that obesity is a disease and not due to lack of motivation, willpower, discipline, or laziness,” Robert F. Kushner said.
Researchers determined the prevalence of weight management interventions among patients who were obese and received an obstructive sleep apnea diagnosis.
If CMS doesn’t reconsider its mandate, which forces independent pharmacies to go deep into a hole and lose money, many of them will close.
Researchers explored the differences in off-label prescribing between pharmacists and physicians among a cohort of patients in pediatric palliative care.
Denosumab-Bmwo is approved for all indications of the respective reference products, including osteoporosis and high-risk of fracture due to chemotherapy.
However, investigators did not determine the association between compatibility status and loss-of-signal alarms.
In a search for new treatment and prevention strategies for pain in patients with fibromyalgia, researchers explored bioavailable nutraceuticals and phytochemicals like polyphenols.
GSK announced its ANCHOR-1 and ANCHOR-2 phase 3 trial results for depemokimab’s efficacy and safety in treating patients with chronic rhinosinusitis with nasal polyps.
Patients in the study could tolerate food allergens more, with fewer adverse events or reactions, compared with multi-allergen oral immunotherapy.
